TriangleNCT00932893 · OUTCOME
Overall Survival Probability at Months 6 and 12
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percent chance of survival
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Month 6, 12
What was measured
Overall survival probability at Month 6 and 12 was defined as the probability of survival at 6 and 12 months respectively, after the randomization of study treatment. The survival probability was estimated using the Kaplan-Meier method.
Analysis population: FAS included all participants who were randomized to study treatment.
Groups in this outcome
Crizotinib
Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
Chemotherapy
Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
| Group | Source count |
|---|---|
| Crizotinib | 173 |
| Chemotherapy | 174 |
Reported measurements
Month 6
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Crizotinib | 86.6 | Not reported | 80.5 | 90.9 | Not reported |
| Chemotherapy | 83.8 | Not reported | 77.4 | 88.5 | Not reported |
Month 12
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Crizotinib | 70.4 | Not reported | 62.9 | 76.7 | Not reported |
| Chemotherapy | 66.7 | Not reported | 59.1 | 73.2 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 80.5
- upper Limit
- 90.9
- value
- 86.6
- group Id
- OG001
- lower Limit
- 77.4
- upper Limit
- 88.5
- value
- 83.8
- title
- Month 6
- categories
- measurements
- group Id
- OG000
- lower Limit
- 62.9
- upper Limit
- 76.7
- value
- 70.4
- group Id
- OG001
- lower Limit
- 59.1
- upper Limit
- 73.2
- value
- 66.7
- title
- Month 12
- denoms
- counts
- group Id
- OG000
- value
- 173
- group Id
- OG001
- value
- 174
- units
- Participants
- description
- Overall survival probability at Month 6 and 12 was defined as the probability of survival at 6 and 12 months respectively, after the randomization of study treatment. The survival probability was estimated using the Kaplan-Meier method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
- id
- OG000
- title
- Crizotinib
- description
- Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.
- id
- OG001
- title
- Chemotherapy
- param Type
- NUMBER
- population Description
- FAS included all participants who were randomized to study treatment.
- reporting Status
- POSTED
- time Frame
- Month 6, 12
- title
- Overall Survival Probability at Months 6 and 12
- type
- SECONDARY
- unit Of Measure
- percent chance of survival
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice